Diclac ID 150mg 20 modified release tablets — Made in Germany — Free Delivery

(Diclac ID )
Diclac ID 150mg 20 modified release tablets — Made in Germany — Free Delivery
Availability: In Stock
Salutas Pharma GmbH Brand: Salutas Pharma GmbH

Indications.

Relief of pain and inflammation of varying degrees in a variety of conditions, including:
  • joint pathology: rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute attacks of gout
  • acute musculoskeletal diseases such as periarthritis (for example, periarthritis of the shoulder scapula), tendonitis, tendovaginitis, bursitis,
  • other pathological conditions caused by trauma, including fractures, back pain, sprains, dislocations, orthopedic, dental and other minor surgical interventions.

Contraindications

Hypersensitivity to the active substance or to any other component of the preparation.
Acute stomach or intestinal ulcer; gastrointestinal bleeding or perforation, history of gastrointestinal bleeding or perforation after use of nonsteroidal anti-inflammatory preparations (NSAIDs), history of acute or recurrent gastric or intestinal ulcer (two or more separate episodes of established ulcer or history of bleeding).
Diclofenac, like other NSAIDs, is contraindicated in patients who, in response to the use of acetylsalicylic acid or other NSAIDs, develop angioedema, nasal polyps, attacks of bronchial asthma, urticaria, acute rhinitis and other allergic symptoms.
Hematopoietic disorders of unknown origin.
Cerebrovascular bleeding or other type of bleeding.
Inflammatory bowel disease (Crohn's disease or ulcerative colitis).
Liver failure.
Renal failure
Congestive heart failure (NYHA II-IV).
Ischemic heart disease in patients with angina pectoris, myocardial infarction.
Peripheral artery disease.
Cerebrovascular disease in patients who have had a stroke or have episodes of transient ischemic attacks.
Treatment of PERIOPERATIVE pain with coronary artery bypass grafting (or the use of a heart-lung machine).
Treatment of postoperative pain after coronary artery bypass grafting (or heart-lung machine).

Compound

active substance: diclofenac;
1 tablet contains diclofenac sodium 75 mg or 150 mg
excipients: lactose, hypromellose (hydroxypropyl methylcellulose), microcrystalline cellulose, calcium hydrogen phosphate, corn starch, sodium starch (type A), colloidal silicon dioxide, magnesium stearate, iron oxide red (E172), purified water.

Method of administration and dosage.

The dose is selected by the doctor individually, starting with the minimum effective dose. To minimize side effects, the lowest effective dose should be used for a short period of time to control symptoms, taking into account the treatment goals of each individual patient.
The recommended starting dose for adults is 75-150 mg per day, depending on the severity of the symptoms of the disease. With long-term therapy, as a rule, it is sufficient to use 1 tablet (75 mg) per day. If the symptoms of the disease are most pronounced during the night or in the morning, DiklakÒ ID should be used in the evening.
The maximum daily dose is 150 mg and should not be exceeded. DiklakÒ ID is intended for short-term use (maximum 2 weeks).
The duration of treatment is determined by the doctor.
The tablets should be swallowed whole, without chewing, with a sufficient amount of liquid, preferably during or after a meal.
Children.
Diclac ID is contraindicated for the treatment of children due to the high content of the active substance in the tablet.

Tags: Diclac

There are no reviews for this product.

Write a review

Buyers Online